Caption Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Caption Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-498,400	Closed	-$897K	–	1965
2022 Q2	$897K	Buy	+498,400	New	+$735K	0.01%	919
2021 Q4	–	Sell	-175,000	Closed	-$780K	–	2066
2021 Q3	$780K	Sell	175,000 -525,000	-75%	-$2.53M	0.01%	1100
2021 Q2	$4.06M	Buy	+700,000	New	+$4.1M	0.05%	429
2020 Q4	–	Sell	-50,000	Closed	-$291K	–	1324
2020 Q3	$291K	Sell	50,000 -400,000	-89%	-$2.39M	0.01%	857
2020 Q2	$3.04M	Sell	450,000 -586,500	-57%	-$4.44M	0.1%	274
2020 Q1	$6.59M	Buy	1,036,500 +144,200	+16%	+$1.16M	0.37%	62
2019 Q4	$9.3M	Buy	892,300 +669,800	+301%	+$4.87M	0.31%	71
2019 Q3	$874K	Buy	222,500 +162,500	+271%	+$1.31M	0.05%	404
2019 Q2	$892K	Sell	60,000 -210,000	-78%	-$3.79M	0.04%	390
2019 Q1	$6.7M	Buy	+270,000	New	+$6.77M	0.37%	74
2018 Q4	–	Sell	-48,700	Closed	-$1.43M	–	680
2018 Q3	$1.43M	Buy	+48,700	New	+$1.89M	0.08%	290

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Caption Management's CLVS Position: Q3 2022 in Review

Caption Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 182,455 shares — an estimated $328K sold.

Caption Management first reported a position in CLVS in Q3 2018 and held it in 7 quarters. The position peaked at $892K in Q2 2019. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

Caption Management reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
Caption Management sold 182,455 Clovis Oncology, Inc. shares in Q3 2022, an estimated $328K.
Caption Management first reported a position in Clovis Oncology, Inc. in Q3 2018 and held it in 7 quarters.
Caption Management's Clovis Oncology, Inc. position peaked at $892K in Q2 2019.
103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Caption Management's 13F filing for Q3 2022, filed 14 Nov 2022.